DDInter810 DDInter1340
Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa.
Originally approved by the FDA in 1989, omeprazole is a _proton-pump inhibitor_, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs . Omeprazole is generally effective and well-tolerated, promoting its popular use in children and adults [FDA label].
Gefitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pantoprazole
Pantoprazole {u} (Compound) resembles {v} (Compound) Omeprazole
Gefitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Esomeprazole
Esomeprazole {u} (Compound) resembles {v} (Compound) Omeprazole
Gefitinib {u} (Compound) binds {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is bound by {v} (Compound) Omeprazole
Gefitinib {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Omeprazole
Gefitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pantoprazole
Pantoprazole {u} (Compound) resembles {v} (Compound) Esomeprazole
Esomeprazole {u} (Compound) resembles {v} (Compound) Omeprazole
Gefitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Esomeprazole
Esomeprazole {u} (Compound) resembles {v} (Compound) Pantoprazole
Pantoprazole {u} (Compound) resembles {v} (Compound) Omeprazole
Gefitinib {u} (Compound) binds {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) is bound by {v} (Compound) Rabeprazole
Rabeprazole {u} (Compound) resembles {v} (Compound) Omeprazole
Gefitinib {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Pantoprazole
Pantoprazole {u} (Compound) resembles {v} (Compound) Omeprazole
Gefitinib {u} (Compound) causes {v} (Side Effect) Alanine aminotransferase increased
Alanine aminotransferase increased {u} (Side Effect) is caused by {v} (Compound) Pantoprazole
Pantoprazole {u} (Compound) resembles {v} (Compound) Omeprazole
Gefitinib {u} (Compound) causes {v} (Side Effect) Hypokalaemia
Hypokalaemia {u} (Side Effect) is caused by {v} (Compound) Esomeprazole
Esomeprazole {u} (Compound) resembles {v} (Compound) Omeprazole
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole (Compound) resembles Omeprazole (Compound)
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole (Compound) resembles Omeprazole (Compound)
Gefitinib (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Omeprazole (Compound)
Gefitinib (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Omeprazole (Compound)
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole (Compound) resembles Esomeprazole (Compound) and Esomeprazole (Compound) resembles Omeprazole (Compound)
Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole (Compound) resembles Pantoprazole (Compound) and Pantoprazole (Compound) resembles Omeprazole (Compound)
Gefitinib (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Rabeprazole (Compound) and Rabeprazole (Compound) resembles Omeprazole (Compound)
Gefitinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pantoprazole (Compound) and Pantoprazole (Compound) resembles Omeprazole (Compound)
Gefitinib (Compound) causes Alanine aminotransferase increased (Side Effect) and Alanine aminotransferase increased (Side Effect) is caused by Pantoprazole (Compound) and Pantoprazole (Compound) resembles Omeprazole (Compound)
Gefitinib (Compound) causes Hypokalaemia (Side Effect) and Hypokalaemia (Side Effect) is caused by Esomeprazole (Compound) and Esomeprazole (Compound) resembles Omeprazole (Compound)